MA32561B1 - Anticorps neutralisant le cytomegalovirus humain et leurs utilisations - Google Patents

Anticorps neutralisant le cytomegalovirus humain et leurs utilisations

Info

Publication number
MA32561B1
MA32561B1 MA33614A MA33614A MA32561B1 MA 32561 B1 MA32561 B1 MA 32561B1 MA 33614 A MA33614 A MA 33614A MA 33614 A MA33614 A MA 33614A MA 32561 B1 MA32561 B1 MA 32561B1
Authority
MA
Morocco
Prior art keywords
antibodies
antibody fragments
human cytomegalovirus
neutralize human
relates
Prior art date
Application number
MA33614A
Other languages
Arabic (ar)
English (en)
Inventor
Antonio Lanzavecchia
Annalisa Macagno
Original Assignee
Inst Research In Biomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41550776&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32561(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Research In Biomedicine filed Critical Inst Research In Biomedicine
Publication of MA32561B1 publication Critical patent/MA32561B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01D—HARVESTING; MOWING
    • A01D34/00—Mowers; Mowing apparatus of harvesters
    • A01D34/01—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus
    • A01D34/412—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters
    • A01D34/63—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters having cutters rotating about a vertical axis
    • A01D34/71—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters having cutters rotating about a vertical axis with means for discharging mown material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01D—HARVESTING; MOWING
    • A01D2101/00—Lawn-mowers
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01D—HARVESTING; MOWING
    • A01D34/00—Mowers; Mowing apparatus of harvesters
    • A01D34/01—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus
    • A01D34/412—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters
    • A01D34/63—Mowers; Mowing apparatus of harvesters characterised by features relating to the type of cutting apparatus having rotating cutters having cutters rotating about a vertical axis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des anticorps neutralisants, et des fragments d'anticorps de ceux-ci, ayant un pouvoir élevé de neutralisation de hcmv, où lesdits anticorps et fragments d'anticorps sont spécifiques d'un, ou d'une combinaison de deux ou plus, produit(s) de gène ul de hcmv. L'invention concerne en outre des lymphocytes b immortalisés qui produisent, et des épitopes qui se lient à, de tels anticorps et fragments d'anticorps. De plus, l'invention concerne l'utilisation des anticorps, fragments d'anticorps et épitopes dans des procédés de criblage ainsi que dans le diagnostic, la prévention et la thérapie de maladies.
MA33614A 2008-07-16 2011-02-11 Anticorps neutralisant le cytomegalovirus humain et leurs utilisations MA32561B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8133408P 2008-07-16 2008-07-16
PCT/IB2009/006641 WO2010007533A2 (fr) 2008-07-16 2009-07-15 Anticorps neutralisant le cytomégalovirus humain et utilisation de ceux-ci

Publications (1)

Publication Number Publication Date
MA32561B1 true MA32561B1 (fr) 2011-08-01

Family

ID=41550776

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33614A MA32561B1 (fr) 2008-07-16 2011-02-11 Anticorps neutralisant le cytomegalovirus humain et leurs utilisations

Country Status (31)

Country Link
US (21) US8603480B2 (fr)
EP (3) EP3178845A1 (fr)
JP (5) JP5422649B2 (fr)
KR (1) KR101356350B1 (fr)
CN (3) CN103980363B (fr)
AU (1) AU2009272284C1 (fr)
BR (1) BRPI0916443A2 (fr)
CA (2) CA2730776C (fr)
CL (3) CL2011000084A1 (fr)
CO (1) CO6351801A2 (fr)
CR (2) CR20160355A (fr)
CU (1) CU23953B1 (fr)
DK (2) DK3009449T3 (fr)
EA (1) EA031177B1 (fr)
EC (2) ECSP11010827A (fr)
ES (2) ES2654543T3 (fr)
GT (4) GT201100011BA (fr)
HK (1) HK1220981A1 (fr)
HN (1) HN2011000161A (fr)
IL (7) IL210356A (fr)
MA (1) MA32561B1 (fr)
MX (5) MX2011000543A (fr)
NZ (5) NZ707788A (fr)
PE (7) PE20141435A1 (fr)
PH (1) PH12015500782A1 (fr)
PL (2) PL3009449T3 (fr)
PT (2) PT2352759T (fr)
SG (3) SG191699A1 (fr)
UA (1) UA106354C2 (fr)
WO (1) WO2010007533A2 (fr)
ZA (1) ZA201600335B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) * 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
DK3009449T3 (en) 2008-07-16 2018-08-06 Inst Res Biomedicine Human cytomegalovirus neutralizing antibodies and their use
SG181901A1 (en) 2009-12-23 2012-08-30 4Antibody Ag Binding members for human cytomegalovirus
EP2582389B1 (fr) * 2010-06-16 2018-02-21 Trellis Bioscience, LLC Anticorps humains à affinité élevée contre la protéine gb du cytomégalovirus (cmv) humain
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
LT3243526T (lt) 2010-07-06 2020-02-10 Glaxosmithkline Biologicals S.A. Rnr pristatymas, skirtas keleto imuninio atsako paleidimui
WO2012006378A1 (fr) 2010-07-06 2012-01-12 Novartis Ag Liposomes à lipides ayant une valeur de pka avantageuse pour la délivrance d'arn
RS63983B1 (sr) 2010-08-31 2023-03-31 Glaxosmithkline Biologicals Sa Pegilovani lipozomi za isporuku rnk koja kodira imunogen
CN104945505A (zh) * 2010-09-29 2015-09-30 弗·哈夫曼-拉罗切有限公司 抗体组合物及使用方法
JP2013544504A (ja) * 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
EP3332802A1 (fr) 2011-07-06 2018-06-13 GlaxoSmithKline Biologicals SA Compositions de combinaisons immunogènes et utilisations de celles-ci
US9139659B2 (en) * 2012-03-28 2015-09-22 Genentech, Inc. Idiotypic antibodies and uses thereof
DK2877580T3 (en) 2012-07-27 2019-04-23 Hope City VAT VACCINE TO DELIVER A UL128 COMPLEX AND PREVENT CMV INFECTION
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
PL2888283T3 (pl) 2012-08-24 2019-03-29 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
WO2016055950A1 (fr) 2014-10-08 2016-04-14 Novartis Ag Combinaison d'anticorps de neutralistion du cytomégalovirus humain
EP3048114A1 (fr) * 2015-01-22 2016-07-27 Novartis AG Antigènes du cytomégalovirus et leurs utilisations
IL254887B2 (en) 2015-04-07 2023-11-01 Alector Llc Anti-sortilin antibodies and methods of using them
EP3347045A4 (fr) 2015-09-10 2019-08-28 City of Hope Anticorps générés par le vaccin mva-gh/gl-pc neutralisant le pouvoir infectieux du cytomégalovirus humain et procédés associés
CN105296588A (zh) * 2015-10-16 2016-02-03 常州市第一人民医院 一种检测肾移植患者在术后感染巨细胞病毒危害程度的方法
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2017153954A1 (fr) 2016-03-11 2017-09-14 Pfizer Inc. Polypeptide gb de cytomégalovirus humain
CN109071665B (zh) 2016-04-18 2022-11-01 塞德斯医疗公司 结合人cd40的激动性抗体及其用途
US11230591B2 (en) 2016-04-20 2022-01-25 Merck Sharp & Dohme Corp. CMV neutralizing antigen binding proteins
WO2017196819A2 (fr) * 2016-05-09 2017-11-16 Icahn School Of Medicine At Mount Sinai Anticorps anti-cytomégalovirus humain (hcmv) largement neutralisant et leurs procédé d'utilisation
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
WO2018031903A1 (fr) 2016-08-12 2018-02-15 Streck, Inc. Contrôles de référence moléculaires
CN106519027B (zh) * 2016-11-11 2019-09-17 深圳先进技术研究院 抗h7n9全人源单克隆抗体5j13及其制法与应用
US11484570B2 (en) 2017-04-14 2022-11-01 University Of Massachusetts Targeting cell tropism receptors to inhibit cytomegalovirus infection
EP3612550A1 (fr) 2017-04-19 2020-02-26 GlaxoSmithKline Biologicals S.A. Protéines de cytomégalovirus modifiées et complexes stabilisés
CN107325178A (zh) * 2017-06-29 2017-11-07 佛山市南海区普罗圣塔生物科技有限公司 一种抗人巨细胞病毒卵黄抗体及其制备方法和应用
WO2019183375A1 (fr) * 2018-03-22 2019-09-26 Eureka Therapeutics, Inc. Agents d'anticorps reconnaissant spécifiquement le transporteur monocarboxylate 4 et leurs utilisations
KR20210011919A (ko) 2018-04-17 2021-02-02 셀덱스 쎄라퓨틱스, 인크. 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai
JP2022505094A (ja) 2018-10-17 2022-01-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変されたサイトメガロウイルスタンパク質及び安定化された複合体
CN109580944A (zh) * 2018-12-07 2019-04-05 潍坊医学院 一种人巨细胞病毒检测试纸及其制造方法
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN109738631A (zh) * 2019-01-21 2019-05-10 潍坊医学院 一种人巨细胞病毒IgM抗体检测试纸的制备方法
WO2020176871A1 (fr) * 2019-02-28 2020-09-03 Ann And Robert H. Lurie Children's Hospital Of Chicago Anticorps contre la maladie de kawasaki identifiant des peptides d'hépacivirus
WO2020208082A1 (fr) * 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode de traitement des maladies liées au cytomégalovirus
CN112898414B (zh) * 2019-12-04 2024-05-10 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
EP4126931A1 (fr) * 2020-03-27 2023-02-08 GlaxoSmithKline Biologicals S.A. Anticorps de liaison à pentamère de hcvm
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
CA3230585A1 (fr) * 2021-09-03 2023-03-09 Domenico Tortorella Anticorps anti-hcmv et leurs fragments de liaison a l'antigene
CN116162154B (zh) * 2022-10-21 2024-06-11 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
CN115947869B (zh) * 2022-11-28 2023-12-12 广州佰芮慷生物科技有限公司 一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4294817A (en) 1977-11-25 1981-10-13 International Diagnostic Technology, Inc. Method of fluoro immunoassay
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4313927A (en) 1979-10-19 1982-02-02 Ames-Yissum Ltd. Immunoassay method for detecting viral antibodies in whole blood samples
US4334016A (en) 1980-06-19 1982-06-08 The Wistar Institute Of Anatomy And Biology Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
FR2543570B1 (fr) 1983-03-31 1985-08-09 Pasteur Institut Anticorps monoclonaux anticytomegalovirus humains, hybridomes secreteurs de ces anticorps et polypeptides porteurs d'un determinant antigenique sequentiel de cytomegalovirus humains
US4617379A (en) 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
GB8404368D0 (en) 1984-02-20 1984-03-28 Cogent Ltd Monoclonal antibodies to human cytomegalovirus
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
FR2563630B1 (fr) 1984-04-27 1988-02-19 Pasteur Institut Anticorps monoclonaux anticytomegalovirus et procedes pour le diagnostic in vitro des infections par les cytomegalovirus humains et d'une proteine-kinase inductible par les cytomegalovirus et susceptible d'etre reconnue par les susdits anticorps monoclonaux
US4783399A (en) 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
US4743562A (en) 1984-08-21 1988-05-10 The Board Of Trustees Of The Leland Stanford Junior University Purified human cytomegalovirus protein
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
WO1986002092A1 (fr) 1984-09-28 1986-04-10 Teijin Limited Hybridome homme-souris produisant un anticorps humain antiviral, procede de preparation et anticorps monoclonal humain antiviral
US4808518A (en) 1985-02-11 1989-02-28 University Of Tennessee Research Corporation Recovery of cytomegalovirus antigen and use thereof in an assay
US4804627A (en) 1985-05-09 1989-02-14 Sloan-Kettering Institute For Cancer Research Method for cloning lymphoblastoid cells
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0248909B1 (fr) 1985-12-06 1994-08-17 Teijin Limited Anticorps monoclonal humain contre le virus megalocytique et procede de preparation dudit anticorps
US6162620A (en) 1986-03-07 2000-12-19 Cogent Limited Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5153311A (en) 1986-11-24 1992-10-06 The Children's Hospital, Incorporated Immunogenic glycoproteins of human cytomegalovirus gCII
US5126130A (en) 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
LU86752A1 (fr) 1987-01-30 1988-08-23 Univ Bruxelles Procede de production d'anticorps monoclonaux humains(igg)anticytomegalovirus et anticorps monoclonaux ainsi obtenus
FI884924A (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
US5180813A (en) 1989-03-24 1993-01-19 University Of Iowa Research Foundation Early envelope glycoprotein of human cytomegalovirus (hmcv) and monoclonal antibodies to the glycoproteins
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
WO1991004277A1 (fr) 1989-09-14 1991-04-04 Children's Biomedical Research Institute Anticorps monoclonaux specifiques contre une glycoproteine de cytomegalovirus
WO1991005876A1 (fr) 1989-10-20 1991-05-02 Children's Biomedical Research Institute Cocktail d'anticorps monoclonaux specifiques du cytomegalovirus humain
GB9008223D0 (en) 1990-04-11 1990-06-13 Royal Free Hosp School Med Improvements relating to the detection of viruses
DE4035174A1 (de) 1990-11-06 1992-05-07 Biotest Ag Verfahren zur bestimmung von proteinen in koerperfluessigkeiten und mittel zur durchfuehrung des verfahrens
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
JPH053794A (ja) 1991-06-26 1993-01-14 Green Cross Corp:The 抗サイトメガロウイルスヒトモノクローナル抗体およびその産生細胞
DE4128684A1 (de) 1991-08-29 1993-03-04 Behringwerke Ag Hcmv-spezifische peptide, mittel dazu und ihre verwendung
DE69227623T2 (de) 1992-04-10 1999-05-20 Erland Uppsala Hanas Verfahren zum Nachweis einer CMV-Infektion
SE9201281L (sv) 1992-04-23 1993-10-24 Bioinvent Int Ab Nya humana monoklonala antikroppar och förfarande för framställning därav
JPH05260961A (ja) 1992-05-21 1993-10-12 Teijin Ltd サイトメガロウイルスに対するヒト・モノクローナル抗体を産生するハイブリドーマ
GB9221654D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
ES2131188T3 (es) 1993-01-21 1999-07-16 Erna Moller Prevencion y tratamiento de citomegalovirus utilizando aminopeptidasa.
EP0683675A4 (fr) 1993-01-28 1997-05-21 Sandoz Pharmaceuticals Corp Anticorps monoclonaux humains contre le cytomegalovirus.
US5750106A (en) 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
AU6777594A (en) 1993-04-30 1994-11-21 Scripps Research Institute, The Human monoclonal antibodies to human cytomegalovirus, and methods therefor
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
EP0702083A3 (fr) 1994-07-26 1997-01-15 Biotest Ag Polypeptides et protéines fusionnées contenant la structure à lecture ouverte UL57 ou la séquence C-terminal de la protéine pp150 de tégument de HCMV, oligonucléotides et trousses diagnostiques correspondantes
US5502652A (en) 1994-08-24 1996-03-26 Hoggatt; Austin C. Method and apparatus for measuring heat transfer in small diameter pipes using acoustic signals
US5783383A (en) 1995-05-23 1998-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of detecting cytomegalovirus (CMV)
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5800981A (en) 1996-02-22 1998-09-01 University Of Limburg Human cytomegalovirus antigen and its use
JP4218985B2 (ja) 1996-07-12 2009-02-04 アクゾ・ノベル・エヌ・ベー ヒトサイトメガロウイルス（ｃｍｖ）を検出するためのペプチド試薬
JP2000516617A (ja) 1996-08-14 2000-12-12 ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー アテローム性動脈硬化病変の出現を予防するか又は遅らせるための方法及び組成物
US7504493B2 (en) * 1997-01-23 2009-03-17 The John Hopkins University Characterization of the yeast transcriptome
JP2001509676A (ja) 1997-01-30 2001-07-24 シーダーズ−サイナイ メディカル センター Ｈｈｖ−８▲上＋▼リンパ腫細胞の確立，産生されるウイルス，抗体，診断方法およびｈｈｖ−８感染の検出のためのキット
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
AU8063798A (en) 1997-06-19 1999-01-04 Regents Of The University Of California, The Secretory immunoglobulin produced by single cells and methods for making and using same
CA2296089A1 (fr) 1997-07-18 1999-01-28 Connaught Laboratories Limited Vaccins d'acide nucleique codant une proteine g du virus respiratoire syncytial
AU749345B2 (en) 1997-11-14 2002-06-27 Connaught Laboratories Limited Alphavirus vectors for paramyxovirus vaccines
DE19756214C1 (de) 1997-12-17 1999-02-25 Biotest Ag Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie
AU754380B2 (en) 1998-03-12 2002-11-14 Genentech Inc. Method of preventing the death of retinal neurons and treating ocular diseases
DE59907027D1 (de) 1998-06-29 2003-10-23 Wolfgang Bergter Antivirale und antiretrovirale radioimmunpharmaka auf der basis von alpha- und beta-strahlern
RU2133472C1 (ru) 1998-09-16 1999-07-20 Унитарное государственное Московское предприятие по производству бактерийных препаратов Способ диагностики активной стадии цитомегаловирусной инфекции человека
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
WO2002066629A2 (fr) 2001-02-21 2002-08-29 Gabriele Hahn Vecteur de recombinaison contenant le genome infectieux du cytomegalovirus humain, conservant les caracteristiques de type sauvage d'isolats cliniques
ITMI20012160A1 (it) 2001-10-18 2003-04-18 Edoardo Marchisio Sistema immunoenzimatico per la caratterizzazione antigenica dell'infezione attiva da cytomegalovirus e cmv confirmation test
CN1188427C (zh) * 2001-12-07 2005-02-09 暨南大学 检测hcmv抗体的重组嵌合肽抗原及其产生方法
US6828113B2 (en) 2002-03-21 2004-12-07 Cornell Research Foundation, Inc. IgM antibodies to the 70 kDa heat shock protein as a marker for cytomegalovirus infection
US8420353B2 (en) 2002-03-22 2013-04-16 Aprogen, Inc. Humanized antibody and process for preparing same
EP1578980A4 (fr) 2002-04-01 2013-01-02 Agensys Inc Acide nucleique et proteine correspondante 213p1f11 que l'on utilise dans le traitement et la detection du cancer
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
DE10232322A1 (de) 2002-07-16 2004-07-29 Hahn, Gabriele, Dr. Viral kodierte CxC determinieren den Gewebetropismus von HCMV
TWI270088B (en) 2002-11-29 2007-01-01 Furukawa Electric Co Ltd Insulated wire and resin dispersion
RU2239453C2 (ru) 2002-12-03 2004-11-10 Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" Препарат иммуноглобулина человека против цитомегаловируса и способ его получения
CN1445243A (zh) * 2002-12-13 2003-10-01 中国疾病控制中心病毒病预防控制所 抗人巨细胞病毒人源中和性基因工程Fab抗体
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
US20040228842A1 (en) 2003-02-27 2004-11-18 Shan Lu Compositions and methods for cytomegalovirus treatment
WO2004078926A2 (fr) 2003-02-28 2004-09-16 Board Of Trustees Operating Michigan State University Marqueurs immunologiques
EP2662390B1 (fr) 2004-06-21 2017-08-02 E. R. Squibb & Sons, L.L.C. Anticorps du récepteur 1 de l'interféron alpha et leurs utilisations
CA2573090A1 (fr) 2004-07-09 2006-01-19 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Differences dans les profils d'expression de genes intestinaux
BE1016287A6 (nl) 2004-07-14 2006-07-04 Picanol Nv Gaapvormingsonderdeel voor een weefmachine en weefmachine.
US7976845B2 (en) 2004-11-29 2011-07-12 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
US7973140B2 (en) 2004-12-21 2011-07-05 Medimmune Limited Antibodies directed to angiopoietin-2 and uses thereof
ATE503770T1 (de) 2005-03-14 2011-04-15 Us Gov Health & Human Serv Humane monoklonale antikörper gegen hendra- und nipah-viren
EP1895898B1 (fr) 2005-06-29 2011-02-16 Compumedics Limited Ensemble capteur a pont conducteur
JP5142458B2 (ja) * 2005-06-30 2013-02-13 キヤノン株式会社 標的物質捕捉分子、標的物質捕捉用の素子、これらを用いた標的物質検出用の装置及びキット、並びに、標的物質の検出方法
ES2367322T3 (es) 2005-12-16 2011-11-02 Ribovax Biotechnologies Sa Métodos para obtener células inmortalizadas que secretan anticuerpos.
JPWO2007094423A1 (ja) 2006-02-15 2009-07-09 株式会社イーベック ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
KR101442209B1 (ko) 2006-05-19 2014-11-18 테크니온 리서치 엔드 디벨로프먼트 화운데이션 엘티디. 융합 단백질, 이의 용도 및 이의 제조방법
EP3031469B1 (fr) * 2006-06-07 2023-08-23 The Trustees Of Princeton University Complexe de protéine de surface du cytomégalovirus destiné à être utilisé dans des vaccins et en tant que cible de médicament
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
AU2007331463B2 (en) 2006-12-15 2014-03-27 Ribovax Biotechnologies Sa Antibodies against human cytomegalovirus (hCMV)
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
WO2008120203A2 (fr) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Procédés de diagnostic et de traitement de maladies provoquées par le cytomégalovirus
US20080248042A1 (en) 2007-04-05 2008-10-09 Irccs Centro Di Riferimento Oncologico Di Aviano, Monoclonal antibody cross-reactive against infective agent causing a B-cell expansion and IgG-Fc
EP2190876A1 (fr) 2007-08-22 2010-06-02 Ribovax Biotechnologies SA Anticorps dirigés contre le cytomégalovirus humain (hcmv)
WO2009085383A1 (fr) 2007-12-19 2009-07-09 Dcb-Usa Llc Anticorps anti-cytomégalovirus humain
WO2010000020A1 (fr) 2008-06-30 2010-01-07 Cathrx Ltd Cathéter
CN102143974B (zh) 2008-07-16 2015-03-25 生命医学研究学会 人巨细胞病毒中和抗体及其用途
DK3009449T3 (en) 2008-07-16 2018-08-06 Inst Res Biomedicine Human cytomegalovirus neutralizing antibodies and their use

Also Published As

Publication number Publication date
PL2352759T3 (pl) 2018-04-30
CN106924729B (zh) 2021-03-02
US20170129939A1 (en) 2017-05-11
US10414817B2 (en) 2019-09-17
UA106354C2 (ru) 2014-08-26
US20170334972A1 (en) 2017-11-23
PT2352759T (pt) 2018-01-08
SG10201706350PA (en) 2017-09-28
CN102203133A (zh) 2011-09-28
PT3009449T (pt) 2018-09-28
US9725502B2 (en) 2017-08-08
SG10201608381SA (en) 2016-11-29
IL232865A (en) 2016-07-31
US9796771B2 (en) 2017-10-24
EA031177B1 (ru) 2018-11-30
HK1220981A1 (zh) 2017-05-19
NZ603498A (en) 2014-02-28
CN106924729A (zh) 2017-07-07
US20180371062A1 (en) 2018-12-27
HN2011000161A (es) 2014-06-09
US9527902B2 (en) 2016-12-27
EP3009449A1 (fr) 2016-04-20
US20100092481A1 (en) 2010-04-15
US20120128692A1 (en) 2012-05-24
EP3009449B1 (fr) 2018-06-06
DK3009449T3 (en) 2018-08-06
NZ603499A (en) 2014-05-30
IL232861A (en) 2016-06-30
WO2010007533A9 (fr) 2017-08-10
IL232862A (en) 2016-06-30
US20160145319A1 (en) 2016-05-26
PE20141432A1 (es) 2014-10-18
CU20110009A7 (es) 2012-06-21
CA2730776C (fr) 2018-12-11
US9221897B2 (en) 2015-12-29
US20170081391A1 (en) 2017-03-23
US20130022618A1 (en) 2013-01-24
IL238421A0 (en) 2015-06-30
JP2015145412A (ja) 2015-08-13
IL232864A (en) 2016-07-31
US20150353627A1 (en) 2015-12-10
CN102203133B (zh) 2015-01-07
IL210356A (en) 2015-06-30
US20140193428A1 (en) 2014-07-10
JP2017055765A (ja) 2017-03-23
JP2011527902A (ja) 2011-11-10
ECSP11010826A (es) 2011-07-29
GT201100011CA (es) 2017-09-14
US9365636B1 (en) 2016-06-14
US9371372B2 (en) 2016-06-21
JP5807050B2 (ja) 2015-11-10
DK2352759T3 (en) 2017-12-18
PE20141433A1 (es) 2014-10-19
US8435524B2 (en) 2013-05-07
MX343250B (es) 2016-10-31
EP2352759A2 (fr) 2011-08-10
GT201100011AA (es) 2017-09-14
IL232862A0 (en) 2014-07-31
US20130302350A1 (en) 2013-11-14
ZA201600335B (en) 2017-11-29
PE20140882A1 (es) 2014-07-25
MX340315B (es) 2016-07-06
PE20141435A1 (es) 2014-10-22
US9796772B2 (en) 2017-10-24
JP6062477B2 (ja) 2017-01-18
AU2009272284A1 (en) 2010-01-21
CA2730776A1 (fr) 2010-01-21
JP5422649B2 (ja) 2014-02-19
CL2011000084A1 (es) 2011-07-01
US8287870B2 (en) 2012-10-16
MX338067B (es) 2016-04-01
JP2018139611A (ja) 2018-09-13
IL210356A0 (en) 2011-03-31
US8124093B2 (en) 2012-02-28
MX343490B (es) 2016-11-08
IL232863A (en) 2016-06-30
BRPI0916443A2 (pt) 2017-10-31
IL232861A0 (en) 2014-07-31
US8603480B2 (en) 2013-12-10
EA201170205A1 (ru) 2011-08-30
US9803000B1 (en) 2017-10-31
PE20110413A1 (es) 2011-06-25
US20170129940A1 (en) 2017-05-11
NZ707788A (en) 2016-08-26
IL232863A0 (en) 2014-07-31
US20120128691A1 (en) 2012-05-24
US20210087257A1 (en) 2021-03-25
AU2009272284B2 (en) 2012-04-05
US10889632B2 (en) 2021-01-12
SG191699A1 (en) 2013-07-31
US10040845B2 (en) 2018-08-07
US20160280769A1 (en) 2016-09-29
CL2014001293A1 (es) 2014-12-05
KR101356350B1 (ko) 2014-01-27
US8298539B2 (en) 2012-10-30
NZ591056A (en) 2013-02-22
ES2682596T3 (es) 2018-09-21
JP6703037B2 (ja) 2020-06-03
PH12015500782A1 (en) 2015-12-14
US9127049B2 (en) 2015-09-08
EP2352759B1 (fr) 2017-11-01
CL2016001340A1 (es) 2016-10-28
GT201100011DA (es) 2017-09-20
US20200017575A1 (en) 2020-01-16
EP3178845A1 (fr) 2017-06-14
CR20160355A (es) 2016-10-11
CN103980363B (zh) 2017-04-12
CU23953B1 (es) 2013-10-29
IL238421A (en) 2016-06-30
JP2014087337A (ja) 2014-05-15
WO2010007533A3 (fr) 2010-08-12
IL232864A0 (en) 2014-07-31
NZ619953A (en) 2015-06-26
MX2011000543A (es) 2011-04-27
IL232865A0 (en) 2014-07-31
CA3022196A1 (fr) 2010-01-21
ECSP11010827A (es) 2011-07-29
CO6351801A2 (es) 2011-12-20
US20140205615A1 (en) 2014-07-24
US9491906B2 (en) 2016-11-15
PL3009449T3 (pl) 2018-09-28
KR20110052585A (ko) 2011-05-18
AU2009272284C1 (en) 2014-05-15
PE20141434A1 (es) 2014-10-22
US8765132B2 (en) 2014-07-01
ES2654543T3 (es) 2018-02-14
US20160096880A1 (en) 2016-04-07
WO2010007533A2 (fr) 2010-01-21
CR20110091A (es) 2011-06-24
PE20141398A1 (es) 2014-10-18
US20160280770A1 (en) 2016-09-29
CN103980363A (zh) 2014-08-13
US9249213B2 (en) 2016-02-02
JP6345753B2 (ja) 2018-06-20
GT201100011BA (es) 2017-09-14
US20110268746A1 (en) 2011-11-03
US20180086819A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
MA32561B1 (fr) Anticorps neutralisant le cytomegalovirus humain et leurs utilisations
MA32566B1 (fr) Anticorps neutralisant les cytomégalovirus humains et leurs utilisations
MA31225B1 (fr) Anticorps neutralisants des cytomegalovirus humains et leur utilisation
MA32577B1 (fr) Anticorps neutralisants le virus de l'influenza a et leurs utilisations
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
MA34461B1 (fr) Anticorps anti-peptide beta-amyloide n3pgiu et leurs utilisations
MA35174B1 (fr) Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
MA35620B1 (fr) Compositions pour le traitement de l'arthrite rhumatoïde et procédés d'utilisation desdites compositions
MA34524B1 (fr) Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3)
MY182750A (en) Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis
MA35928B1 (fr) Thérapie combinée d'anticorps contre le csf -1r humain et ses utilisations
MA34749B1 (fr) Anticorps anti-récepteur de la barrière hémato-encéphalique à faible affinité et leurs utilisations
WO2006085984A3 (fr) Biocapteurs de cellules immunes et procedes d'utilisation
WO2006076025A3 (fr) Biocapteurs de cellule immune et procede d'utilisation de ceux-ci
WO2008108803A3 (fr) Biocapteurs de cellules immunitaires et méthodes d'utilisation correspondantes
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
MA31991B1 (fr) Anticorps contre le virus de la grippe et procedes pour leur utilisation
MA33757B1 (fr) Protéines de liaison à l'antigène de l'il-23 humaine
MA35345B1 (fr) Proteines de liaisons a un antigene ayant une liaison accrue a fcrn
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA31984B1 (fr) Formulation d'anticorps
NO20090069L (no) Malrettede forbindelser rettet mot binding til PDGFR-alfa og deres anvendelse
WO2011092593A3 (fr) Anticorps neutralisant le vih-1 et leurs utilisations
WO2010041149A3 (fr) Procédés et compositions pour diagnostic et traitement
WO2004037198A3 (fr) Induction de la mort de cellules tumorales provoquee par un anticorps